Scynexis BREXAFEMME® (ibrexafungerp tablets) Commercial Launch Update
About The Event
The event will feature presentations by the SCYNEXIS management team who will discuss its H2:2021 commercial launch plans for BREXAFEMME® (ibrexafungerp tablet), the first approved drug from a novel antifungal class in over 20 years. Also featured will be Key Opinion Leader Michael L. Krychman, M.D.C.M. (Southern California Center for Sexual Health and Survivorship Medicine), a renowned physician specializing in Obstetrics and Gynecology, who will discuss how BREXAFEMME fits into the vaginal yeast treatment landscape.
The SCYNEXIS management team and Dr. Krychman will be available to answer questions following the formal presentations.